NCT06330896View on ClinicalTrials.gov

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing

Not yet recruitingOBSERVATIONAL

Enrollment

498

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

April 1, 2028

Conditions

Plasma Cell Disorder

All Listed Sponsors

lead

Siriraj Hospital

OTHER

NCT06330896 - Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing | Biotech Hunter | Biotech Hunter